The FDA’s Center for Devices and Radiological Health has issued an alert concerning packaging failures associated with MediHoney Wound and Burn products, as well as specific lots of CVS Wound Gel. This warning underscores the critical nature of maintaining the integrity of sterile medical products.
As of December 19, 2025, the alert reports 11 serious injuries linked to MediHoney products and three related to CVS Wound Gel. Fortunately, no fatalities have been associated with these incidents, according to the FDA’s findings.
Manufacturer Notification
Integra LifeSciences, the manufacturer of these products, has taken steps to notify affected customers. They recommended the immediate removal of the compromised items from both use and sale. MediHoney products, which feature manuka honey, and CVS Wound Gel are essential in treating wounds and burns, as they create moist environments that safeguard the skin against damage and irritation.
On January 16, Integra LifeSciences formally informed customers about the issue, highlighting production and process control failures that affected certain CVS Wound Gel items. The FDA warns that using products with compromised sterile barriers significantly heightens the risk of infection.
Customer Guidance
In its communication, Integra LifeSciences instructed customers to quarantine the affected products and disseminate the notice to anyone who may possess them. They also advised the disposal of any expired units. Distributors are encouraged to identify and eliminate the impacted products from their inventory, notify customers about affected shipments, and obtain complete response forms from anyone reporting further issues.
The FDA has urged consumers to refrain from using the products in question, emphasizing the importance of maintaining safety standards in medical care.
Clinical Implications
For clinicians who have utilized these products and adhered to standard care protocols, the FDA has indicated that additional patient follow-ups are not necessary. This recent alert serves as a reminder that even widely used wound care products can become hazardous if sterility is compromised. A breach in the sterile barrier increases the potential for contamination and subsequent infections.
Standard Wound Care Recommendations
In managing routine postsurgical wounds that are clean and not infected, the recommendation remains straightforward: maintain moisture with plain petrolatum jelly covered by a nonadherent dressing. A practical tip for patients is to utilize a new, unopened container of petrolatum, as repeated usage of an open jar can elevate the risk of contamination.
Hydrocolloid dressings represent another effective option, as they can remain in place for up to a week, simplifying wound care while promoting a moist healing environment.
Addressing Infection Risks
If there are concerns regarding early superficial infections, a prescription topical antibiotic like mupirocin is typically recommended. Over-the-counter options such as bacitracin or neomycin are not advisable due to their potential to cause allergic reactions and irritation, which can hinder the healing process.
Patients should also consult their physicians regarding the necessity of oral antibiotics, particularly for deeper infections that topical treatments cannot adequately address.
Evaluating Honey-Based Dressings
Honey-based dressings have garnered attention for their antimicrobial and anti-inflammatory properties in specific contexts, especially for burns and select chronic wounds. However, their effectiveness can vary based on the type of wound and the formulation used. Potential drawbacks of honey include allergic reactions, increased drainage, maceration, and contamination risks associated with non-medical-grade honey.
While some patients may be drawn to honey for its natural appeal, it is not the first-line treatment for uncomplicated surgical wounds. Nevertheless, there is a legitimate role for honey in wound care, provided that medical-grade products are used appropriately.
Conclusion
The FDA’s alert regarding packaging failures in MediHoney and CVS Wound Gel products highlights the importance of vigilance in wound care. It reminds healthcare providers and patients alike to prioritize safety and efficacy when selecting wound management solutions. Awareness and adherence to guidelines can significantly mitigate risks associated with compromised sterile products.
- Key Takeaways:
- FDA warns against using MediHoney and CVS Wound Gel due to packaging failures.
- 14 serious injuries reported; no fatalities linked to the issue.
- Recommended standard care for clean surgical wounds includes petrolatum jelly or hydrocolloid dressings.
- Honey-based dressings have potential benefits but come with risks and should be medical-grade.
- Consult healthcare providers for appropriate antibiotic treatments based on wound severity.
Read more → www.healio.com